Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Tuesday, April 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced it will report its first quarter 2025 financial results on May 6, 2025. Following the announcement, there will be a live conference call and webcast led by the company's senior management to discuss the results and provide a business update. The conference call will be accessible to investors and interested parties via phone and will also be streamed online, with an option to replay for 90 days.
Price reaction · baseline $19.41 (2025-04-28 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel is actively engaging with investors through a scheduled conference call.
  • The webcast will provide insights into financial results and business updates.
  • The company is focused on improving patient lives through novel therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit  www.rigel.com.
Contact for Investors & Media:
Rigel Pharmaceuticals, Inc.
Email: [email protected]

Frequently Asked Questions

When will Rigel Pharmaceuticals report its Q1 2025 results?

Rigel Pharmaceuticals will report its Q1 2025 financial results on May 6, 2025.

What time is Rigel's conference call after the earnings report?

The conference call will take place at 4:30 p.m. Eastern Time.

How can I access the live conference call?

Participants can dial 877-407-3088 for domestic and 201-389-0927 for international access.

Where can I find the archived webcast of the conference call?

The archived webcast will be available on Rigel's website for 90 days.

What is the focus of Rigel Pharmaceuticals?

Rigel focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals financial results business update biotechnology hematic disorders
Last updated: Apr 29, 2025

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →